Sanofi has opened its new modular manufacturing facility in Singapore.
Located in Tuas Biomedical Park, the Modulas site can produce both next-generation vaccines and biologic-based therapeutics simultaneously.
According to Sanofi, the facility has been specifically designed to manufacture up to four vaccines or biopharmaceuticals in parallel.
The facility can also the equivalent to 34 standardised production modules — all of which are interconnected — to allow the rapid configuration of production lines depending on what is needed.
This new facility was built to enhance Sanofi's preparedness for future increases in biopharmaceutical manufacturing; this includes potential pandemics.
Sanofi's Executive VP of Manufacturing and Supply, Brendan O’Callaghan, commented: “By leveraging cutting-edge technology, the latest in digital innovation and advanced data analytics, Modulus will help accelerate the delivery of life-changing treatments to address unmet medical needs.
“More than just a factory, it redefines healthcare delivery with flexibility and speed, enabling us to meet the changing needs of the pipeline across multiple modalities, as well as respond with urgency to future public health challenges.”
The site will also feature green technology, while being constructed with recycled materials.
Sanofi estimates that the Modulus facility will be fully operational by mid-2026, and will create around 200 new skilled positions.
Png Cheong Boon, Chair of the Singapore Economic Development Board, added: “Through its novel modular concept manufacturing facility, Sanofi will boost its ability to produce life-saving therapeutics and vaccines, and potentially for future pandemics."
“The facility will create good jobs for Singaporeans across diverse roles in our growing biopharmaceutical sector, and we look forward to partnering with more companies keen to serve global healthcare needs from Singapore.”
